Markus Brückner, Tobias M Nowacki, Friederike Cordes, Dominik Bettenworth, Department of Medicine B, University Hospital of Münster, D-48149 Münster, Germany.
World J Gastroenterol. 2017 Apr 28;23(16):2899-2911. doi: 10.3748/wjg.v23.i16.2899.
To study mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) and vascular endothelial growth factor (VEGF)-targeted contrast enhanced ultrasound (CEUS) for the assessment of murine colitis and carcinogenesis.
C57BL/6 mice were challenged with 3% dextran sodium-sulfate (DSS) for three, six or nine days to study the development of acute colitis. Ultrasound was performed with and without the addition of unspecific contrast agents. MAdCAM-1-targeted contrast agent was used to detect and quantify MAdCAM-1 expression. Inflammatory driven colorectal azoxymethane (AOM)/DSS-induced carcinogenesis was examined on day 42 and 84 using VEGF-targeted contrast agent. Highly specific tissue echogenicity was quantified using specialized software. Sonographic findings were correlated to tissue staining, western blot analysis and immunohistochemistry to quantify the degree of inflammation and stage of carcinogenesis.
Native ultrasound detected increased general bowel wall thickening that correlated with more progressed and more severe DSS-colitis (healthy mice: 0.3 mm ± 0.03 six days DSS: 0.5 mm ± 0.2 nine days DSS: 0.6 mm ± 0.2, < 0.05). Moreover, these sonographic findings correlated well with clinical parameters such as weight loss ( = 0.74) and histological damage ( = 0.86) ( < 0.01). In acute DSS-induced murine colitis, CEUS targeted against MAdCAM-1 detected and differentiated stages of mild, moderate and severe colitis calculation of mean pixel contrast intensity in decibel (9.6 dB ± 1.6 12.9 dB ± 1.4 18 dB ± 3.33, < 0.05). Employing the AOM/DSS-induced carcinogenesis model, tumor development was monitored by CEUS targeted against VEGF and detected a significantly increased echogenicity in tumors as compared to adjacent healthy mucosa (healthy mucosa, 1.6 dB ± 1.4 42 d, 18.2 dB ± 3.3 84 d, 18.6 dB ± 4.9, < 0.01). Tissue echogenicity strongly correlated with histological analysis and immunohistochemistry findings (VEGF-positive cells in 10 high power fields of healthy mucosa: 1 ± 1.2 42 d after DSS start: 2.4 ± 1.6 84 d after DSS start: 3.5 ± 1.3, < 0.01).
Molecularly targeted CEUS is a highly specific and non-invasive imaging modality, which characterizes murine intestinal inflammation and carcinogenesis .
研究黏膜地址素细胞黏附分子-1(MAdCAM-1)和血管内皮生长因子(VEGF)靶向对比增强超声(CEUS)在评估小鼠结肠炎和癌变中的作用。
用 3%葡聚糖硫酸钠(DSS)对 C57BL/6 小鼠进行 3、6 或 9 天的刺激,以研究急性结肠炎的发展。在添加和不添加非特异性造影剂的情况下进行超声检查。使用 MAdCAM-1 靶向造影剂来检测和量化 MAdCAM-1 的表达。在第 42 天和第 84 天,使用 VEGF 靶向造影剂检测和评估由炎症驱动的结直肠氧化偶氮甲烷(AOM)/DSS 诱导的癌变。使用专门的软件对高度特异性组织回声进行定量。将超声结果与组织染色、Western blot 分析和免疫组织化学相关联,以量化炎症程度和癌变阶段。
原始超声检测到的肠壁整体增厚与更严重和更严重的 DSS 结肠炎相关(健康小鼠:0.3mm±0.03;6 天 DSS:0.5mm±0.2;9 天 DSS:0.6mm±0.2,<0.05)。此外,这些超声发现与体重减轻(=0.74)和组织学损伤(=0.86)等临床参数密切相关(<0.01)。在急性 DSS 诱导的小鼠结肠炎中,针对 MAdCAM-1 的 CEUS 检测和区分了轻度、中度和重度结肠炎(平均像素对比强度的分贝计算值分别为 9.6dB±1.6、12.9dB±1.4、18dB±3.3,<0.05)。在 AOM/DSS 诱导的癌变模型中,使用针对 VEGF 的 CEUS 监测肿瘤的发展,并在肿瘤中检测到明显高于相邻健康黏膜的回声强度(健康黏膜,1.6dB±1.4;42d 时,18.2dB±3.3;84d 时,18.6dB±4.9,<0.01)。组织回声强度与组织学分析和免疫组织化学发现密切相关(健康黏膜中 10 个高倍视野的 VEGF 阳性细胞数:1±1.2;DSS 开始后 42d:2.4±1.6;DSS 开始后 84d:3.5±1.3,<0.01)。
分子靶向 CEUS 是一种高度特异和非侵入性的成像方式,可用于描述小鼠肠道炎症和癌变的特征。